1 citations
,
August 2025 in “International Journal of Molecular Sciences” Nutraceutical insulin-sensitizing agents may help treat skin conditions like psoriasis and acne.
1 citations
,
November 2005 in “Journal of Andrology” The meeting highlighted promising genetic treatments for male fertility issues but noted concerns about certain cancer risks and ICSI safety.
April 2026 in “The Open Biotechnology Journal” Resveratrol shows health benefits but faces challenges in effectiveness and regulation.
April 2026 in “Metabolites” Chronic skin diseases and metabolic syndrome are linked by shared inflammation pathways.
January 2026 in “Therapeutics” SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.
January 2026 in “International Journal of Molecular Sciences” Brimonidine is effective for reducing facial redness in skin conditions and has potential for broader dermatological uses.
January 2026 in “Aging and Disease” DKK proteins could help diagnose and treat various non-cancerous diseases.
October 2025 in “Frontiers in Pharmacology” Arctium lappa L. might help treat immune-related skin diseases, but more research is needed.
January 2025 in “Applied Sciences” Sulforaphane from broccoli may help treat certain cancers, hormone issues, and hair loss.
December 2024 in “Pharmaceutics” Extracellular vesicles show promise for treating psoriasis by reducing inflammation and skin lesions.
August 2024 in “Aesthetic Plastic Surgery” Exosome treatment safely increases hair density in male patients with androgenetic alopecia.
August 2024 in “Drug Design Development and Therapy” Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
October 2022 in “Biomedicines” Finasteride in male rats causes liver and metabolic issues in their offspring.
154 citations
,
March 2012 in “Indian Journal of Surgical Oncology” PSA is best for detecting prostate cancer recurrence and evaluating treatment response.
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
3 citations
,
May 2014 in “Urologia Journal” 5ARIs lower PSA levels, but other tests are needed to avoid missing aggressive prostate cancer.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
1 citations
,
September 2025 in “Archivio Italiano di Urologia e Andrologia” Serenoa repens extract, alone or with other supplements, improves urinary symptoms and lowers PSA levels.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
1 citations
,
October 2006 in “Oncology times” Finasteride improves prostate cancer detection in PSA test.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
April 2012 in “The Journal of Urology” Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.
March 2009 in “The Journal of Urology” Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.
November 2007 in “Cancer Epidemiology and Prevention Biomarkers” Higher C-peptide levels in African-American men and higher HbA1c levels in Caucasian men are linked to lower PSA levels.
June 2007 in “Nature Clinical Practice Urology” Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.
April 2007 in “Nature Clinical Practice Urology” Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.
February 2007 in “Journal watch” Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
February 2003 in “European Urology Supplements” Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.
October 2025 in “International Journal of Social health” Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.